October 01, 2022
2 min watch
Save
VIDEO: OTX-TKI shows promising results in wet AMD
Issue: November 10, 2022
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this video from Eyecelerator@AAO, Peter Kaiser, MD, discusses data from a phase 1 clinical study investigating OTX-TKI for the treatment of wet age-related macular degeneration.
In the randomized double-masked study, patients were randomly assigned to receive either OTX-TKI (axitinib intravitreal implant) or aflibercept every 8 weeks. According to Kaiser, chief medical advisor, retina, Ocular Therapeutix, OTX-TKI had positive results, showing a “dramatic reduction in treatment burden” in the treated cohort.
Published by:
Sources/Disclosures
Collapse
Source:
Kaiser P. Ocular Therapeutix. Presented at: Eyecelerator@AAO; Sept. 29, 2022; Chicago.
Disclosures:
Kaiser reports consulting for Bayer, Ocular Therapeutix and Regeneron.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.